Trevi Therapeutics closed at $13.98 on Nov 4, up 0.90%, 28.3% below its 52-week closing high. Volume of 1.4M shares was 0.56× its 20-day average (below normal).
Split-adjusted performance: +6.1% over one month, -1.9% over six months, +30.7% over one year.
Short interest was 16.0M shares at the Oct 15 settlement, up 9.3% from the prior report (14.4% of float, 4.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TRVITrevi Therapeutics | $13.99 | +0.90% | −1.9% | — | — | — | $1.99B | |
| HRMYHarmony Biosciences Holdings | $34.42 | −7.04% | +5.0% | +30.3% | 28.9% | 11.1 | $2.00B | Compare |
| SRPTSarepta Therapeutics, | $18.99 | +2.43% | −17.5% | −34.3% | −1.2% | — | $2.01B | Compare |
| TRAXFirst Tracks Biotherapeutics | $49.04 | +5.83% | — | — | — | — | $2.06B | Compare |
| XERSXeris Biopharma Holdings | $10.46 | +1.06% | +64.2% | +28.7% | −33.8% | — | $1.91B | Compare |
| AGIOAgios Pharmaceuticals | $31.38 | +0.58% | +16.3% | +259.3% | −225.1% | — | $1.87B | Compare |
| SDGRSchrodinger | $28.52 | +4.93% | +119.7% | +7.5% | 10.1% | — | $2.13B | Compare |
| ZBIOZenas BioPharma | $28.46 | +0.28% | +36.6% | — | −11145.6% | — | $1.85B | Compare |
| SLSSELLAS Life Sciences Group | $9.14 | +3.04% | +77.5% | — | — | — | $1.85B | Compare |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
